Regenerative medical devices company Tissue Regenix Group announced the launch of a new operating division on Monday - 'TRX BioSurgery'.
The AIM-traded firm said 'DermaPure', a decellularised, room-temperature stable dermal allograft, would be the flagship product under the TRX BioSurgery division.
Currently commercialised under Tissue Regenix Wound Care, which would begin operating as 'TRX BioSurgery', DermaPure had proven successful in multiple surgical applications.
Due to DermaPure's impressive single application clinical outcomes, the board said it had been adopted by surgeons within the acute surgical, wound reconstruction, and traditional advanced wound care markets.
In particular, DermaPure said it had seen "significant" uptake in the orthopaedic trauma and urogynaecology segments, where treatment innovation was in high demand.
In order to further expand the opportunity, Tissue Regenix said it had entered an exclusive distribution partnership with ARMS Medical - a specialist distributor in the urogynaecology segment.
The multi-year agreement would give ARMS Medical exclusive rights to distribute DermaPure to hospitals and surgeons throughout the United States for use in urology and gynecology procedures.
Tissue Regenix said the partnership would allow its direct sales force to maintain their focus on soft tissue regeneration in the wound, plastics, orthopaedics and general surgery markets.
"We are excited to announce the launch of the BioSurgery division," said CEO Steve Couldwell.
"Progressing from traditional wound care clinical settings to surgical applications is a natural evolution for DermaPure, which has proven to be clinically efficient in just a single application.
"Our partnership with ARMS Medical, who are known for bringing innovation to women's pelvic health solutions, allows us to leverage their strong relationships with key opinion leaders in the urogynaecology space to further access this market, whilst also maintaining commercial focus in our other key areas."